Suominen Corporation’s stock exchange release on September 16, 2026 at 6:30 p.m. (EEST)

Changes in the Suominen Leadership Team

As we continue to transform Suominen and strengthen our performance, we are further developing the capabilities and ways of working needed to execute our strategy and realize the full potential of our business.

To strengthen our strategic execution and the leadership needed to drive this change, we are making changes in the Suominen Leadership Team, effective September 17, 2026.

Eevaleena Mäki-Uuro, Senior Vice President, Commercial Excellence and Strategic Projects, has been appointed Chief Strategy and Transformation Officer (CSTO) and member of the Suominen Leadership Team. In her new role, Eeva will report to President and CEO Charles Héaulmé.

Eevaleena brings international experience in strategic and transformation projects from both management consulting and the process industry. Prior to Suominen, she worked in strategy, sustainability and business leadership roles at Huhtamäki. Her background also includes management consulting at Bain & Company.

“I’m pleased to welcome Eevaleena to our team. She has a significant track record in raising strategic programs, bringing people together, planning and executing complex cross-functional initiatives”, says Charles Héaulmé, President and CEO Suominen.

Anni Luoma, General Counsel, has been appointed Chief Legal Officer and member of the Suominen Leadership Team. In her new role, Anni will report to Charles Héaulmé.

Anni joined Suominen as Legal Counsel in 2022 and was promoted to General Counsel in 2024. Prior to Suominen, she worked at Neles, currently part of Valmet, as well as at Metso and Metso Outotec.

“Anni works effectively and closely with our leadership team and the Board of Directors on legal and compliance matters, and I am happy to welcome her to our team”, says Charles Héaulmé.

Suominen’s current Chief Strategy and Transformation Officer (previously also acting as Interim General Counsel) Marika Väkiparta has decided to leave the company to pursue other professional endeavors. She will continue with Suominen until the end of October 2026, focusing on strategic projects.

“Marika has played an important role in shaping and advancing Suominen’s transformation. Her contribution has been instrumental in establishing the direction and foundations for our Full Potential Program and in driving several strategic initiatives across the company. I would like to thank Marika for her commitment, leadership and contribution to Suominen. The work she has done provides a strong foundation for us to continue our transformation and improve our performance”, says Charles Héaulmé.

Suominen Leadership Team as of September 17, 2026:

  • Charles Héaulmé, President and CEO
  • Kimmo Raunio, Chief Financial Officer
  • Francois Guetat, Chief Operating Officer
  • Markku Koivisto, Chief Commercial and Technology Officer
  • Anni Luoma, Chief Legal Officer
  • Eevaleena Mäki-Uuro, Chief Strategy and Transformation Officer
  • Liisa Pursiheimo, Chief Human Resource Officer

SUOMINEN CORPORATION
Board of Directors

Further information:

Charles Héaulmé, President and CEO, tel. +358 10 214 3268

Distribution:

Nasdaq Helsinki
Key media
www.suominen.fi

About Suominen Corporation

Suominen manufactures nonwovens as roll goods for wipes and other applications. Our vision is to be the frontrunner for nonwovens innovation and sustainability. The end products made of Suominen’s nonwovens are present in people’s daily life worldwide. Suominen’s net sales in 2025 were EUR 412.4 million and we have almost 700 professionals working in Europe and in the Americas. Suominen’s shares are listed on Nasdaq Helsinki. Read more at www.suominen.fi.

Attachments

– Increased or Maintained Dividend for Over 33 Consecutive Years –

GREAT NECK, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) — One Liberty Properties, Inc. (NYSE: OLP) today announced that its Board of Directors declared a quarterly dividend on the Company’s common stock of $0.45 per share. The dividend is payable on October 6, 2026 to stockholders of record at the close of business on September 24, 2026, and represents One Liberty’s 135th consecutive quarterly dividend. One Liberty has increased or maintained its dividend for over 33 consecutive years.

About One Liberty Properties, Inc:

One Liberty is an industrial focused real estate investment trust organized in Maryland in 1982. The Company owns and operates a geographically diversified portfolio consisting primarily of industrial properties across the United States. Additional financial and descriptive information on One Liberty, its operations and its portfolio, is available on its website at: http://1liberty.com. Interested parties are encouraged to review One Liberty’s Annual Report on Form 10-K and the other reports it files with the Securities and Exchange Commission for additional information.

Contact:
One Liberty Properties
Investor Relations
Phone: (516) 466-3100
http://1liberty.com

LONDON and PHILADELPHIA, Sept. 16, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces today that it has achieved clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate (PDC) platform in the ongoing phase 1 FOCUS-01 trial.

Preliminary data from the Phase 1a trial of AVA6103 in patients with select solid tumors demonstrate proof of mechanism with two key findings:

  •  AVA6103 pre|CISION® controlled-release exatecan demonstrates a clean safety profile through the first three dose levels, including a payload dose level 50% higher than the maximum tolerated dose (MTD) of conventional exatecan, and
  •  The comparison of the preclinical modeled pharmacokinetic (PK) data and clinical trial PK data demonstrates an exceptional alignment through the first 3 dose levels with controlled release of exatecan evident in patients for days after dosing

The alignment of these critical datasets greatly increases our confidence that the safety profile, tumor selectivity and antitumor efficacy observed in the preclinical studies of AVA6103 will translate into the clinic.

The first head-to-head comparison of AVA6103 and Enhertu®, a marketed antibody drug conjugate (ADC) that targets HER2, demonstrates that AVA6103 shows better antitumor activity vs. Enhertu®, with deep and durable responses delivered by our dose dense regimen that has been applied in the FOCUS-01 trial.

Christina Coughlin, CEO of Avacta, commented:

“We are thrilled to report the proof of mechanism data with our first Next-Generation pre|CISION® molecule in the clinic, which continues to underscore the potential of our platform to make a significant difference to cancer patients. AVA6103 moved from candidate status to Investigational New Drug application in less than a year, and has now reached an initial clinical readout with excellent safety and PK data, showing it is performing exactly as expected from the data generated in our preclinical studies.  

“Our head-to-head comparison with the marketed ADC Enhertu® shows better activity in a HER2+ preclinical model even at low FAP levels, with the dose-dense regimen demonstrating advantages of AVA6103 over traditional dosing of ADCs.

“We continue our discussions with potential partners on the Next Gen assets and these data greatly increase our partnering position across the Next Gen platform. The FOCUS-01 trial continues to enroll patients into two parallel arms and we look forward to providing further updates as the trial progresses.

“With FAP expression in ~90% of solid tumors, these clinical findings provide a gateway for Avacta to link multiple payloads and access previously unaddressable markets.  This is a major inflection point for our Next Gen pre|CISION® platform, providing the opportunity for pipeline expansion to benefit patients and shareholders alike.”

Clinical Proof of Mechanism of AVA6103 in the FOCUS-01 Trial

Trial design and progress:

The FOCUS-01 Phase 1 clinical trial of AVA6103 is enrolling patients with locally advanced or metastatic disease with one of six indications, being: colorectal cancer, pancreatic ductal adenocarcinoma, gastric/gastroesophageal junction cancers, cervical cancer or small cell lung cancer. 

  • The first three dose levels have completed enrollment of patients (n=19) in two parallel arms with doses administered every two weeks (Q2W) or every three weeks (Q3W) and assessed for safety and tolerability, PK / pharmacodynamics (PD) and preliminary efficacy. The first three dose levels in the AVA6103 trial were 1.5 mg/m2, 3 mg/m2 and 4.5 mg/m2 to enable the comparison to both the Phase 1 trial of Enhertu® and conventional exatecan:
    • The first three dose levels are similar to the absolute payload dose levels in the published Enhertu® Phase 1 trial (Doi, et al. 2017);
    • Dose level 2 of AVA6103 is similar to the MTD of conventional exatecan (Rowinsky, et al. 2000); and
    • Dose level 3 represents an approximate 50% increase over this MTD of conventional exatecan.  

Safety, tolerability and PK data in the first three dose levels are presented.  Screening is ongoing for enrollment of patients into both the Q2W and Q3W arms at dose level 4.

Safety data
Patients in the FOCUS-01 trial were treated with escalating doses (1.5 mg/m2 to 4.5 mg/m2) and assessed for safety and tolerability. These data were compared with published data for Enhertu® (releasing a highly similar payload, deruxtecan) and with conventional exatecan administered in the standard regimen (once daily for five days).   

  • The safety profile of AVA6103-derived exatecan is highly favorable at the first three dose levels when compared with equivalent dosing of topoisomerase I inhibitors (Topo Ii) (conventional exatecan and Enhertu-derived deruxtecan), with minimal toxicity reported with AVA6103.
  • Notably, AVA6103 produced little toxicity at the equivalent and escalated doses of the MTD of conventional exatecan in heavily pretreated patients (Rowinsky et al. 2000) and at similar payload doses in the first three cohorts in the Phase 1 of Enhertu® (Doi et al. 2017). Relevant comparison data include:
    • Neutropenia: 0% with AVA6103, 22% with similar doses of Enhertu, and 64% at the MTD of conventional exatecan (equivalent to the 3 mg/m2 dose of AVA6103).
    • Thrombocytopenia: 5% (1/19) with AVA6103, 11% with Enhertu® and 43% with conventional exatecan;
    • Anemia: 16% (3/19) with AVA6103, 11% with similar doses of Enhertu® and 43% with conventional exatecan; and
    • Nausea and vomiting: 5% (1/19) with AVA6103, 44% with Enhertu® and 67% with exatecan (reported across all dose levels in this trial). 

Pharmacokinetic data

Patients were assessed for plasma PK properties across the first three dose levels of AVA6103 and compared to the corresponding dose levels of Enhertu®. 

  • As seen previously in preclinical models, the first three dose levels in the trial demonstrate rapid reduction in the plasma level of the PDC (AVA6103), with prolonged low-level release of both products of the cleavage reaction, the pre|CISION® peptide and released exatecan.
  • Given the very short half-life of the released peptide (2-3 hours) that was demonstrated in the AVA6000 program, and the detection of low levels of the released peptide from AVA6103 in the plasma up to 48 hours after dosing indicates that the PDC is being retained in the tumor in a ‘drug reservoir’ that is slowly being cleaved to release the peptide and exatecan, as this mechanism was designed to do.
  • The remarkable consistency of these results with predictive PK modeling based on preclinical studies greatly increase our confidence that AVA6103 is performing as intended, and that the robust preclinical data will translate to the clinic and support ongoing dose-escalation and efficacy evaluation in the Phase 1 trial.

Preclinical efficacy comparison with Enhertu®

  • The comparative efficacy of Enhertu® and AVA6103 was tested in a head-to-head format using a gastric cancer patient-derived xenograft model that is HER2+ and FAP+ (by IHC).
  • When tumors had grown to 100-200 mm3 in size, animals were randomized to receive either AVA6103 or Enhertu® at the preclinical dose with evidence of activity (Enhertu® x 1 or AVA6103 QWx3 dose dense regimen). 
  • Enhertu® treatment resulted in a slowed growth compared to vehicle control, with two animals demonstrating small tumor reductions and 1/6 with progression as best response.  In comparison, AVA6103 treatment resulted in deep and prolonged partial responses in 6/6 animals treated.  

Outlook

  • The design of the FOCUS-1 trial of AVA6013 and preclinical updates will be presented in Trials in Progress presentations at both the American Association of Cancer Research (AACR) Conference on Pancreatic Cancer, being held on September 25-28, 2026, and the European Society for Medical Oncology (ESMO) Congress, being held on October 23-27, 2026.
  • First efficacy data from the FOCUS-01 trial with AVA6103 is anticipated to be presented in H1 2027 – including data from clinical tumor biopsies which are anticipated to confirm AVA6103 is being retained in a ‘drug reservoir’ in the tumor, based on the preliminary Phase 1 data.
  • The selection of the payloads and data to support clinical candidate selection for the Dual Payload Next Gen Program (AVA6207) will be presented in Q4 2026.
  • Clinical data from the First Gen faridoxorubicin (AVA6000) program will also be presented in Q4 2026 at the ESMO Congress.

Enhertu® (trastuzumab deruxtecan; T-DXd) is a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product). Enhertu® is a registered trademark of Daiichi Sankyo Company, Limited and AstraZeneca.

Doi et al. 2017. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncology (2017). 18(11):1512-22. doi: 10.1016/S1470-2045(17)30604-6

Rowinsky et al. 2000. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. Journal of Clinical Oncology (2000). 18(17):3151-63. doi:10.1200/JCO.200.18.17.31

–Ends–

For further information from Avacta, please contact:

Avacta Group plc
Christina Coughlin, Chief Executive Officer
https://avacta.com/
via Cohesion Bureau
   
Strand Hanson Limited (Nominated Adviser)
James Harris / Chris Raggett / James Dance
www.strandhanson.co.uk
Zeus (Broker)
James Hornigold / George Duxberry / Dominic King
www.zeuscapital.co.uk
Cohesion Bureau
Communications / Media / Investors
Richard Jarvis
avacta@cohesionbureau.com

 

   

About Avacta – https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta’s innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

Our pre|CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer. 

About FAP-Exd (AVA6103)

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. 

–Ends–

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Tornator Oyj

Stock Exchange Release, 16 September 2026 at 6 PM

Tornator Oyj issues EUR 300 million green notes

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO ANY PERSON LOCATED OR RESIDENT IN, OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE AND SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Tornator Oyj (“Tornator“) issues senior secured green notes in the aggregate principal amount of EUR 300 million (the “Notes“). The Notes will mature on 23 January 2033 and carry a fixed annual interest of 4.50 per cent. The issue date for the notes will be on 23 September 2026. The Notes are issued in accordance with Tornator’s green finance framework published in spring 2026 (the “Framework“).

The Notes are secured by certain forest properties owned by Tornator which form a dynamic security pool that secures also Tornator’s other secured indebtedness.

Tornator shall use the net proceeds from the issue of the Notes to refinance and finance Tornator’s existing indebtedness, including redeeming the EUR 350m 1.250% notes due 14 October 2026 (ISIN: FI4000442108). An amount equivalent to the net proceeds of the Notes will be used for financing and refinancing eligible green assets in accordance with Tornator’s Framework.

“The new bond issue refinances maturing debt and secures the financing capacity required to implement Vision 2035 for several years ahead. At the same time, the successful issuance reflects the long-term and stable nature of Tornator’s business, as well as the positive impact of maintaining strong investor relationships”, says Antti Siirtola, Tornator’s Chief Financial Officer.

Tornator will submit an application to have the Notes listed on the official list of sustainable bonds of Nasdaq Helsinki Ltd.

Danske Bank A/S, OP Corporate Bank plc and Skandinaviska Enskilda Banken AB (publ) act as Joint Lead Managers for the issue of the Notes (the “Joint Lead Managers“).

For further information, please contact:

CFO Antti Siirtola, tel. +358 40 773 0975

www.tornator.fi/en

Tornator is a leading European company specialising in sustainable forestry. It owns forests in Finland, Estonia and Romania. In 2025, the Group’s revenue totalled approximately EUR 232 million and its balance sheet amounted to about EUR 4.0 billion. The Group directly employs around 190 people. Altogether, the company’s forests provide approximately 1,600 full time equivalent jobs through Tornator’s own personnel as well as entrepreneurs and their employees. The parent company’s owners are Finnish, mainly institutional investors. Tornator’s mission is to create sustainable well being from forests.

Important information

This release is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of Tornator. The distribution of this release and the related material concerning the issuance of the Notes may, in certain jurisdictions, be restricted by law. No actions have been taken to register or qualify the Notes, or otherwise to permit a public offering of the Notes, in any jurisdiction. If Tornator decides to proceed with the issue of the Notes, any offering material or documentation related to the Notes may be received only in compliance with applicable exemptions or restrictions. Persons into whose possession this release or any such offering material or documentation may come are required to inform themselves of and observe all such restrictions. This release and any such offering material or documentation may not be distributed or published in any country or jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction or would require actions under the laws of a state or jurisdiction. In particular, this release and any such offering material or documentation may not be distributed in the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa and this release and any related material concerning the issuance of the Notes may not be sent to any person in the before mentioned jurisdictions.

The Notes will not be registered under the U.S. Securities Act 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state of the United States. The Notes may not be offered, sold, pledged or otherwise transferred directly or indirectly within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the Securities Act (“Regulation S”)), except to a person who is not a U.S. Person (as defined in Regulation S) in an offshore transaction pursuant to Regulation S.

The Notes are not intended to be offered, sold, distributed or otherwise made available to and should not be offered, sold, distributed or otherwise made available to any retail investor in the United Kingdom (the “UK”). For the purposes of this provision, a retail investor means a person who is either one (or both) of the following: (i) not a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA; or (ii) not a qualified investor as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024. Consequently no disclosure document required by the FCA Product Disclosure Sourcebook (DISC) for offering, selling or distributing the Notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering, selling or distributing the Notes or otherwise making them available to any retail investor in the UK may be unlawful under DISC and the Consumer Composite Investments (Designated Activities) Regulations 2024.

Expands New Jersey retail footprint to five dispensaries

Dispensary generates over US$10 million in annualized revenue and will be immediately accretive to EBITDA and cash flow

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — TerrAscend Corp. (the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced that its consolidated entities (together with the Company, “TerrAscend”) have closed on the previously announced transaction with Aunt Mary’s Dispensary LLC (“Aunt Mary’s”), located in Hunterdon County, New Jersey. Aunt Mary’s is TerrAscend’s fifth retail location in New Jersey and will be immediately accretive to TerrAscend on an EBITDA and free cash flow basis.

“Aunt Mary’s generates more than US$10 million in annualized revenue today, and we see meaningful opportunities to enhance sales and profitability through the integration of our premium brand portfolio,” said Jason Wild, Executive Chairman of TerrAscend. “We are excited to welcome the Aunt Mary’s team to the TerrAscend family.”

In June 2026, TerrAscend entered into an agreement with Aunt Mary’s and the other parties named therein for total consideration of US$9 million, comprised of (i) US$3 million in the form of a five-year unsecured convertible debenture (the “Debenture”) bearing interest at 6.0% per annum (subject to the Company’s right to pay interest in kind at the interest rates provided for and in accordance with the terms and conditions of the Debenture) for an option to purchase 35% of Aunt Mary’s (the “Option”) and (ii) US$6 million payable in cash upon exercise of the Option.

The transaction conforms to New Jersey’s regulatory framework, which facilitates investment opportunities for diversely owned businesses. Upon exercise of the Option and additional conditions, the transaction will allow the Company to fully consolidate the business in its financial results and increase TerrAscend’s consolidated retail footprint to a total of 21 dispensaries across five U.S. states and Canada.

About TerrAscend Corp.
TerrAscend Corp. is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including operations in Pennsylvania, New Jersey, Maryland, Ohio, and California through TerrAscend Growth Corp. and retail operations in Canada. TerrAscend operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including The Apothecarium, Cookies, Kind Tree, Legend, State Flower, Wana, Cuue, One and Valhalla. For more information visit www.terrascend.com.

Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. On April 23, 2026, the U.S. Department of Justice issued a final rule rescheduling marijuana contained in United States Food and Drug Administration (“FDA”)-approved drug products and marijuana subject to a state medical marijuana license from Schedule I to Schedule III of the Controlled Substances Act (“CSA”), which became effective on April 28, 2026. However, any form of marijuana other than in an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a Schedule I controlled substance under the CSA, and those who handle such material remain subject to the regulatory controls and administrative, civil, and criminal sanctions applicable to Schedule I controlled substances. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. The enforcement of federal laws in the United States is a significant risk to the business of the Company and any proceedings brought against the Company thereunder may adversely affect the Company’s operations and financial performance.

Forward-Looking Information and Forward-Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements and forward-looking information are intended to be covered by the safe harbor provisions for forward-looking statements contained in those sections and the Private Securities Litigation Reform Act of 1995. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include, but are not limited to, statements regarding the expected benefits and expected financial contribution of the Aunt Mary’s transaction, including anticipated EBITDA and free cash flow accretion; the occurrence, timing and expected outcome of the exercise of the Option and the satisfaction of additional conditions, including the full consolidation of Aunt Mary’s in the Company’s financial results and the expansion of TerrAscend’s consolidated retail footprint; statements with respect to the Company’s expectations with respect to its business outlook, financial profile, and operational efficiencies; and its market opportunities, growth prospects in existing markets, and M&A strategy.. Forward-looking information and forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information and forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking information and forward-looking statements because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information and forward-looking statements are subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information and forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk that the expected benefits of the Aunt Mary’s transaction, including the expected accretion to EBITDA and free cash flow, may not be realized; the risk that the Option may not be exercised or that the conditions to full consolidation of Aunt Mary’s in the Company’s financial results may not be satisfied; the risk that the integration of Aunt Mary’s does not proceed as anticipated; current and future market conditions; risks relating to federal, state, provincial, territorial, local and foreign laws, rules and regulations, including U.S. federal and state laws relating to cannabis operations in the U.S.; and such risk factors set out in the Company’s most recently filed MD&A, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and in the section titled “Risk Factors” in the Company’s Annual Report for the year ended December 31, 2025 filed with the Securities and Exchange Commission on March 12, 2026, as updated by its Quarterly Reports on Form 10-Q.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information or forward-looking statements, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

For more information regarding the Company:
Eric Jackson
Chief Financial Officer
IR@terrascend.com
689-345-4114

Investor Relations Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
TerrAscend@KCSA.com 
212-896-1254

Company positioned highest for Ability to Execute and recognized for its Completeness of Vision

News Summary

  • Nutanix is recognized as a Leader in the 2026 Gartner® Magic Quadrant™ for Server Virtualization Platforms. This recognition arrives at a pivotal moment for IT leaders, many of whom are actively reassessing their virtualization strategy amidst industry consolidation, rising costs, and increasingly restrictive licensing models.
  • Nutanix is positioned highest for Ability to Execute and recognized for its Completeness of Vision.
  • As organizations navigate the transition from legacy environments to modern AI-ready hybrid architectures, Nutanix offers a proven, future-ready platform that prioritizes infrastructure freedom, operational simplicity, and technological superiority. Unlike legacy virtualization stacks that are being forced into rigid, “all-or-nothing” enterprise bundles, Nutanix delivers modular licensing that enables organizations to consume capabilities appropriate to their needs and modernize at their own pace. 

Why it Matters

The recognition evaluates Nutanix’s capabilities in server virtualization and comes as organizations continue to readjust to the changing virtualization industry landscape. Nutanix Cloud Infrastructure (NCI), with its built-in AHV hypervisor based on proven open-source KVM virtualization technology, brings together compute, storage, networking and virtualization as the infrastructure foundation for Nutanix Cloud Platform (NCP), providing a unified way to run, manage, and govern VMs, containers, and AI workloads across distributed environments. 

SAN JOSE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Nutanix (NASDAQ: NTNX), a hybrid cloud leader and AI platform company, today announced it has been recognized as a Leader in the 2026 Gartner Magic Quadrant for Server Virtualization Platforms. 

Nutanix Cloud Infrastructure (NCI), with its built-in AHV hypervisor, provides the infrastructure foundation of Nutanix Cloud Platform (NCP), helping organizations run and manage workloads across hybrid cloud environments. NCI brings together compute, storage, networking, and virtualization capabilities to provide a consistent operating model across different infrastructure environments.

“As organizations modernize their infrastructure and prepare to run agentic AI at scale, they need a platform that gives them flexibility without added complexity and silos,” said Ketan Shah, Vice President of Product Management, Nutanix. “We believe being named a Leader in the 2026 Gartner® Magic Quadrant™ for Server Virtualization Platforms highlights how Nutanix empowers customers to run AI, virtual machines, and containers seamlessly across an expanding choice of clouds, sovereign locations, server and storage architectures, and managed service providers.”   

Nutanix continues to support a broad range of workloads by offering flexible deployment architectures across an expanding list of server and storage hardware as well as public cloud locations, giving customers more flexibility and enabling them to leverage their existing investments when supply chains are constrained. Recent milestones include the general availability of support for Dell PowerStore, major updates for Everpure FlashArray and Dell PowerFlex, as well as limited availability of NetApp ONTAP, extending the range of infrastructure options customers can use while maintaining a consistent operating model. 

Nutanix also recently introduced a full-stack Agentic AI solution that includes a secure, high-performance virtualization foundation for AI infrastructure. The solution brings together compute, networking, storage, and Kubernetes services to run AI workloads efficiently across hybrid cloud environments. 

Nutanix also recently announced a strategic neocloud partnership with ChronoScale to extend its platform capabilities into accelerated compute and AI services.  

In total, these advancements are designed to help customers modernize infrastructure while maintaining flexibility, consistent operations, and control across AI, VMs, and container workloads. 

Customer Commentary

“We didn’t just want a replacement for legacy virtualization; we needed a future-proof foundation for our ambitious AI and cloud-native initiatives. With Nutanix, we have a platform that supports our new initiatives right alongside our core enterprise applications and removes a lot of hurdles from our journey.”

– Bhart Panwar, Additional General Manager, BHEL (Bharat Heavy Electricals Limited)

“Nutanix has been instrumental in our infrastructure modernization journey at Ente Autonomo Volturno. By providing a unified operating model that seamlessly bridges our virtualization and container environments, Nutanix allows us to efficiently manage our mission-critical applications and disaster recovery sites. The platform’s proven reliability and ease of use have given our IT team the confidence to innovate and scale our services, while ensuring high availability and operational resilience for the transportation system of the Campania Region.”

— Luciano Ragazzi, IT Director and CISO, Ente Autonomo Volturno 

“Nutanix Cloud Platform gave us the freedom to move away from VMware after it was acquired by Broadcom and deliver a true hybrid cloud model. It allowed us to have a dual-native capacity where services like security, networking, and data protection are unified across both VMs and containers. Finally, it also accelerates our journey to AI with Nutanix Enterprise AI, offering a cloud-native control plane and platform for innovation via a familiar, easily manageable, and integrated environment.” 

– Jasim Abdul Rahman, group CIO, Power International Holding

“Our Nutanix journey started more than a decade ago as a move away from traditional three-tier infrastructure, and today the platform supports around 90% of our on-premises environment. We’ve progressively moved from VMware to AHV, consolidated our core enterprise applications, and expanded the platform to support GPU-enabled teaching and research, self-service infrastructure, and hybrid cloud. What has worked particularly well for us is having a platform that can reliably support the University’s critical systems while continuing to evolve with our needs in areas such as AI, automation, and cloud native.”

– Justin Mason, Associate Director, Technology Services, University of Canberra

“AI and cloud native initiatives are critical to our business, but they also place significant demands on our IT infrastructure. Birlasoft needed a future-ready platform that went beyond simply replacing legacy virtualization. With Nutanix, we now have a modern foundation that supports our innovation roadmap while continuing to run and scale our core enterprise applications.”

– Vinod Krishnan, Global Head – IT, Birlasoft Limited

Gartner, Inc, Magic Quadrant for Server Virtualization Platforms, Tony Harvey, Daniel Bowers, Paul Delory, Tony Iams, Owen Marino, 14 September 2026​

Gartner Disclaimer

Gartner and Magic Quadrant are trademarks of Gartner, Inc. and/or its affiliates.

Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose. 

About Nutanix

Nutanix is a hybrid cloud leader and AI platform company, offering organizations a unified infrastructure software platform to safely run applications, data, and AI anywhere. Trusted by customers worldwide, Nutanix empowers more than 50% of the Global 2000 to innovate faster with AI, while modernizing infrastructure, simplifying operations, and controlling costs. Learn more at www.nutanix.com or follow us on social media.

©2026 Nutanix, Inc. All rights reserved. Nutanix, the Nutanix logo and all Nutanix product and service names mentioned are registered trademarks or trademarks of Nutanix, Inc. in the United States and other countries. Kubernetes is a registered trademark of The Linux Foundation in the United States and other countries. All other brand names mentioned are for identification purposes only and may be the trademarks of their respective holder(s). This content may contain express and implied forward-looking statements, including but not limited to statements regarding our plans and expectations relating to new product features and technology under development, the capabilities of such product features and technology, and our plans to release product features and technology. Such statements are not historical facts and are instead based on our current expectations, estimates and beliefs. The accuracy of such statements involves risks and uncertainties and depends upon future events, including those that may be beyond our control, and actual results may differ materially and adversely from those anticipated or implied by such statements, including, among others: failure to develop, or unexpected difficulties, delays or disruptions in developing, releasing or distributing, new products, services, product features or technology in a timely or cost-effective basis. Any forward-looking statements included speak only as of the date hereof and, except as required by law, we assume no obligation to update or otherwise revise any such forward-looking statements to reflect subsequent events or circumstances. Certain products and features or functionalities described herein remain in varying stages of development and will be offered on a when-and-if-available basis. The development, release, and timing of any such products, features or functionalities are subject to change. Nutanix will not have any liability for any failure to deliver or delay in the delivery of any such products, features or functionalities. Any future product or product feature information is intended to outline general product directions, and is not a commitment, promise, or legal obligation for Nutanix to deliver any functionality. This information should not be used when making a purchasing decision.

CONTACT: Media Contact:
Ken Lotich
pr@nutanix.com

Honor recognizes Roop’s more than 37 years of R&D leadership, customer-focused innovation and contributions to the coatings industry

PHILADELPHIA, Sept. 16, 2026 (GLOBE NEWSWIRE) — Axalta Coating Systems (NYSE: AXTA), a leading global coatings company, today announced that Dr. Robert K. Roop, Senior Vice President and Chief Technology Officer, has received the 2026 Paint & Coatings Industry (PCI) Lifetime Achievement Award. Roop was recognized this morning during the Coatings Trends & Technologies Summit in Lombard, Illinois, for his nearly four decades of technical leadership, innovation and impact to the coatings industry.

The PCI Lifetime Achievement Award recognizes individuals whose outstanding contributions over the course of their careers have advanced the coatings industry. Roop was selected for the breadth and lasting impact of his career, including his leadership in technical innovation, his ability to connect science with customer and business needs, and his commitment to developing the next generation of scientists, engineers and technical leaders.

“Robert’s impact on Axalta and the coatings industry extends far beyond any single technology or achievement,” said Chris Villavarayan, Chief Executive Officer and President of Axalta. “Throughout his career, he has demonstrated an exceptional ability to turn chemistry into meaningful solutions for our customers while building and developing world-class technical teams. His leadership, passion for innovation and commitment to people have helped shape Axalta into the technology leader we are today. We are incredibly proud to see Robert receive this well-deserved recognition.”

Image of Dr. Robert K. Roop standing in front of a wall with colored panels

Roop began his career with DuPont in 1989, holding increasingly senior roles across research, product development, manufacturing, plant management and global technology leadership before joining Axalta when it became an independent company in 2013. Since becoming Axalta’s Chief Technology Officer in 2019, he has led a global organization of approximately 1,300 scientists, engineers and technical professionals across 21 product development laboratories worldwide.

Throughout his career, Roop has helped advance and commercialize coatings technologies for the Transportation and Industrial markets, consistently applying deep technical knowledge and disciplined innovation methods to solve complex business and industry challenges. Under his technical leadership, Axalta technologies have earned 39 external awards since 2019, including nine R&D 100 recognitions, eleven BIG Innovation Awards and nineteen Edison Awards.

Beyond advancing coatings technology, Roop has remained deeply committed to developing people and strengthening Axalta’s technical capabilities. His leadership has helped foster a culture of technical excellence, collaboration and customer-focused innovation across the company’s global technology organization.

“I’ve always been passionate about solving challenging problems through science, but the most rewarding part of my career has been working with talented people and helping them grow,” said Roop. “Seeing the next generation of technical leaders develop and succeed is what continues to motivate me.”

To hear Roop reflect on his career, approach to innovation and perspective on the future of the coatings industry, listen to his interview on PCI’s Coat It! Podcast here.

About Axalta

Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful and sustainable coatings solutions. From light vehicles, commercial vehicles and refinish applications to electric motors, building facades and other industrial applications, our coatings are designed to prevent corrosion, increase productivity and enhance durability. With more than 150 years of experience in the coatings industry, the global team at Axalta continues to find ways to serve our more than 100,000 customers in over 140 countries better every day with the finest coatings, application systems and technology. For more information visit axalta.com and follow us on LinkedIn.

   
Axalta Coating Systems
1050 Constitution Ave.
Philadelphia, PA 19112
axalta.com
Global Media Contact
media-relations@axalta.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b7c3cceb-65ed-4df3-979c-b46204647e29

OCTOPUS AIM VCT PLC

Admission of Further Securities to Trading

Further to the Company’s Issue of Equity and Total Voting Rights announcement on 28 August 2026 in respect of the allotment of new Ordinary Shares under the Company’s Dividend Reinvestment Scheme and following the admission to trading of those new Ordinary Shares, the following additional information is disclosed in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1 Details of the issuer
a) Name Octopus AIM VCT plc
b) LEI 213800C5JHJUQLAFP619
2 Details of the transferable securities admitted to trading
a) Name, type and identification code Ordinary shares of 1p each

ISIN: GB0034202076

b) Regulated market London Stock Exchange – Main Market
c) Number of further securities admitted 2,609,154
d) Total number of securities in issue following admission 250,206,085
e) Fungibility Fully fungible with existing Ordinary shares
3 Admission details
a) Date of admission 4 September 2026
b) Prospectus information Prospectus: N/A

Supplementary: N/A

Company’s webpage: https://octopusinvestments.com/our-products/venture-capital-trusts/octopus-aim-vcts/

c) Coverage of notification All admissions up to and including 4 September 2026

For further information please contact:

Ronan Goggin  
Octopus Company Secretarial Services Limited
Tel: +44 (0)80 0316 2067

LEI: 213800C5JHJUQLAFP619

Consumer Education Campaign to Launch September 17 Across 13 US Markets

BALTIMORE and IRVING, Texas, Sept. 16, 2026 (GLOBE NEWSWIRE) — Sinclair, Inc. (NASDAQ: SBGI), and Nexstar Media Group, Inc. (NASDAQ: NXST), today announced a joint consumer education campaign designed to increase awareness and understanding of NextGenTV, the broadcast technology powered by ATSC 3.0.

Launching September 17, the GoNextGenTV campaign will run across 13 markets served by Sinclair and Nexstar television stations, combining on-air promotion with digital and social content. The campaign is focused on consumer education, designed to make NextGenTV easier for consumers to understand, demonstrating the technology’s improved picture and sound, enhanced broadcast services, greater interactivity, and advanced capabilities of the ATSC 3.0 standard.

Nexstar will take part in the campaign across seven markets: Cleveland, Austin, Kansas City, Tampa, Portland, OR, Buffalo, and Denver. Sinclair will participate in six markets: Las Vegas, Columbus, Nashville, Baltimore, Seattle, and Washington, D.C.

The campaign builds on a successful consumer education initiative developed and tested by Sinclair this summer in Columbus, Ohio.

“Consumer education is an important part of accelerating adoption of NextGenTV,” said Del Parks, President of Technology, Sinclair. “Our experience in Columbus demonstrated that when consumers understand what NextGenTV is, how to access it and the benefits it can deliver, we can meaningfully increase engagement. By partnering with Nexstar, we can take what we learned from that campaign and bring a consistent, consumer-friendly message to viewers across an even broader group of markets.  Now is the time for all broadcasters to begin promoting the advantages of NextGenTV.”

Both companies will use a shared set of campaign resources and direct viewers to GoNextGenTV.com, a consumer website offering information about NextGenTV, compatible devices and availability by market.

“The transition to NextGenTV has been a story of broadcasters working together to bring new capabilities to TV viewers. The cooperation and collaboration with Sinclair to educate those viewers is the next chapter in that story,” said Brett Jenkins, Nexstar’s Executive Vice President and Chief Technology and Digital Officer. “We’re confident that as consumers come to understand the advantages of NextGenTV, they will be eager to adopt it and will seek out TV models with ATSC 3.0 capability.”

The September launch represents the first phase of the joint campaign, with Sinclair and Nexstar using their local market reach and trusted local brands to connect directly with consumers and provide practical information about the transition to NextGenTV.

For more information, visit GoNextGenTV.com.

About Sinclair
Sinclair, Inc. (Nasdaq: SBGI) is a diversified media company and a leading provider of local news and sports. The Company owns, operates and/or provides services to 178 television stations in 79 markets affiliated with all major broadcast networks; owns Tennis Channel, the premium destination for tennis enthusiasts; and multicast networks CHARGE, Comet, ROAR, and The Nest. Sinclair’s content portfolio includes AMP Media, which produces a growing slate of original programming across multiple platforms. For more information, please visit www.sbgi.net.

About Nexstar Media Group, Inc.
Nexstar Media Group, Inc. (NASDAQ: NXST) is a leading diversified media company that produces and distributes engaging local and national news, sports and entertainment content across its television and digital platforms.  For more information, please visit nexstar.tv.

Media contacts:

Sinclair: Jessica Bellucci, jbellucci-c@sbgtv.com

Nexstar: Gary Weitman, gweitman@nexstar.tv 

Category: General

Veteran local bankers Lynn Sanders and Richard Yoskey join EagleBank to lead market growth

BETHESDA, Md., Sept. 16, 2026 (GLOBE NEWSWIRE) — The Bethesda-based holding company for EagleBank, the largest community bank headquartered in Maryland, today announced an expansion of its commercial banking business into Baltimore, extending the Bank’s relationship-focused model to businesses across the market.

EagleBank named Lynn Sanders as market executive for Baltimore and Richard Yoskey as commercial and industrial (C&I) senior relationship manager. Together, they will be responsible for building the Bank’s commercial business in the region and growing a team to serve small and middle-market companies with lending, treasury, acquisition financing, equipment financing and other banking solutions. 

“Baltimore represents a significant growth opportunity for EagleBank and a natural extension of our franchise,” said Steve Curley, President and CEO of EagleBank. “Our strategy is to grow in markets where local knowledge, strong relationships and responsive decision-making can make a difference. Baltimore shares many of the qualities that have driven our success, and we see a clear opportunity to build a strong, lasting commercial banking presence here.” 

“As a Baltimore native, I’ve enjoyed the opportunity to serve clients across the Greater Baltimore area throughout my career. Deepening EagleBank’s relationships with the city’s businesses and communities is a top priority. Our investment in Baltimore starts with local knowledge and experienced people,” said Evelyn Lee, EVP and Chief Lending Officer – Commercial and Industrial at EagleBank. “Lynn and Richard are highly respected bankers with deep roots in the market, strong relationships, and extensive commercial banking experience. They provide EagleBank with a strong foundation to serve Baltimore businesses and grow our presence across the region.” 

Lynn Sanders Background 
Sanders joins EagleBank from Wells Fargo Commercial Banking, where she spent more than a decade serving Maryland-based middle-market and corporate clients. As executive director and senior relationship manager, she managed relationships with Maryland-headquartered and owner-led companies with revenues ranging from $100 million to $14 billion. 

Her experience spans capital markets and syndications, leveraged finance, treasury management, asset-based lending and equipment finance, recruiting and leading commercial banking teams. 

Previously, Sanders worked in M&T Bank’s Corporate Banking Division in Baltimore, managing large corporate relationships. She has recently served on the Boards of Executive Alliance and Downtown Partnership of Baltimore as well as WTCI’s Women Spanning the Globe Advisory Board. 

“Baltimore has an incredibly strong and diverse business community, and I’ve had the privilege of working with companies and business leaders in the area throughout my career,” Sanders said. “EagleBank’s relationship-driven approach and local decision-making are a strong fit for this market, and I’m excited to build our presence here.” 

Richard Yoskey Background 
Yoskey brings more than 20 years of commercial banking, leveraged finance and capital markets experience. Most recently, he served as senior director, capital markets at Baltimore-based Cerebro Capital, where he structured and placed acquisition financing for independent sponsors and founder-owned businesses. 

Previously, Yoskey built CFG Bank’s sponsor finance and cash flow lending platform, developing a national referral network. Earlier in his career, he held commercial and business banking positions with United Bank, Bay Bank, Wells Fargo and Wachovia in Baltimore. 

Yoskey serves on the board of the Association for Corporate Growth Maryland and has longstanding involvement with Baltimore-area business and community organizations. 

“Baltimore businesses value banking partners who understand their companies and the local market,” Yoskey said. “EagleBank combines local decision-making with the capabilities businesses need to grow, and I look forward to building new relationships across the region.” 

About Eagle Bancorp, Inc. and EagleBank
Eagle Bancorp, Inc. is the holding company for EagleBank, which commenced operations in 1998. EagleBank is headquartered in Bethesda, Maryland, and conducts full service commercial banking through 12 offices, located in Suburban, Maryland, Washington, D.C. and Northern Virginia. EagleBank focuses on building relationships with businesses, professionals and individuals in its marketplace

EagleBank Contact
Vikki Kayne
Chief Marketing Officer
301.986.1800

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.